GlassScriptPhysician profile
Raymond J Tasch Ramirez
NPI 1497727341
$1,610.63
in general payments reported to CMS, 2019-2025
11 companies · $75.00 in 2025
The $75.00 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.92 · 2020: $135 · 2021: $408 · 2022: $113 · 2023: $443 · 2024: $364 · 2025: $75.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $538.18 | 2021-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $350.63 | 2020-2025 | Jardiance |
| Eli Lilly Export S.A. Puerto Rico Branch | $195.00 | 2020-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $137.62 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $118.71 | 2023 | Mounjaro |
| Merck Sharp & Dohme LLC | $92.92 | 2019-2023 | Januvia, Janumet, Steglatro |
| Pbg Puerto Rico LLC | $70.00 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $37.37 | 2022-2023 | Eliquis |
| Sanofi-Aventis U.S. LLC | $25.00 | 2022 | |
| Glaxosmithkline, LLC. | $25.00 | 2024 | Trelegy Ellipta |
| Abbvie INC. | $20.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Tasch Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.